Boehringer Ingelheim Suspends BI 3031185 Phase 1 Study, After An Undisclosed Safety Event In Japan

Boehringer Ingelheim has suspended enrollment in a Phase 1 trial of BI 3031185 while it evaluates what the company described only as a “safety event.” The study was running at a hospital in Fukuoka, Japan, and had started in early July.

A spokesperson told Fierce that enrollment is on a voluntary hold because “patient safety is central to Boehringer Ingelheim” and that the assessment is ongoing. The company did not provide details on the nature of the event and also declined to specify BI 3031185’s mechanism of action.

The trial on hold

According to the study description cited by Fierce, the trial has two parts. The first is a single-blind, randomized, placebo-controlled evaluation of the safety, tolerability and pharmacokinetics of single and multiple doses of BI 3031185 in healthy males.

The second part is a non-randomized, open-label assessment of how multiple oral doses of BI 3031185 affect the pharmacokinetics of Bayer’s approved oral contraceptive pill, Yaz, in healthy female participants. That design suggests Boehringer was already building an early interaction package around the asset even before disclosing what therapeutic target it is pursuing.

What is known about BI 3031185

While BI 3031185 remains largely under wraps, Boehringer said the compound had already completed three separate studies. One was a Phase 1b trial in Germany in 78 patients with borderline personality disorder or attention deficit/hyperactivity disorder. That study began in August 2025 and was recently marked complete on the U.S. federal trials database.

Boehringer also ran a Phase 1 study in Germany between October 2025 and January 2026 that evaluated the effect of multiple oral doses of Johnson & Johnson’s antifungal medication Sporanox on the pharmacokinetics of a single oral dose of BI 3031185.

The limited disclosure leaves an unusually narrow basis for interpreting the setback. The practical signal for the sector is that even after multiple early studies, a safety review can still abruptly slow development, and companies may reveal very little until they decide whether a protocol change, dose adjustment or broader program rethink is needed. Until Boehringer provides that update, the hold is a reminder that early-stage clinical risk often becomes visible to outsiders only after enrollment stops.